Psoriasis, Psoriasis Arthritis, Psoriasis Patients, Psoriasis (PsO)
Conditions
Keywords
Comorbidities, Costa Rica, Psoriasis, Real-world data, Disease severity, Epidemiology
Brief summary
The goal of this observational study is to characterize the epidemiologic, clinical, severity, and therapeutic features of patients with psoriasis treated in Costa Rica between 2024 and 2025. The main questions it aims to answer are: What are the demographic and clinical characteristics and severity profiles of psoriasis patients? What treatments are used in routine clinical practice, and how are they associated with disease severity and outcomes? Patients with psoriasis receiving dermatologic care during the study period will be included. Data will be obtained retrospectively from electronic medical records and clinical registries without intervention or modification of treatment.
Detailed description
Psoriasis is a chronic immune-mediated inflammatory dermatosis with variable severity, systemic associations, and substantial quality-of-life impact. Although multiple topical, phototherapy, systemic, and biologic treatments are available, real-world epidemiologic and therapeutic data in Costa Rica remain limited. This study is a retrospective observational characterization of psoriasis patients treated between 2024 and 2025. Unlike interventional trials evaluating specific drugs or prospective registries of targeted therapies, this study analyzes existing clinical records to describe demographic distribution, clinical subtypes, severity (PASI/BSA/DLQI), comorbidities, and treatment patterns across routine care. It does not introduce therapeutic modifications or standardized follow-up, but reflects real-world management decisions across disease severities. By capturing population-level data on psoriasis presentation and treatment in Costa Rica, the study provides baseline national evidence distinct from drug-specific or interventional psoriasis studies.
Interventions
None listed
Sponsors
Caja Costarricense de Seguro Social
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients evaluated in outpatient clinics during the period 2024-2025. * Patients receiving systemic therapy and/or phototherapy. * Patients aged 12 years or older, of any sex. * Availability of sufficient clinical information to assess psoriasis severity, metabolic comorbidities, atherosclerotic cardiovascular disease, and psoriatic arthritis. * At least one dermatologic or rheumatologic evaluation recorded in the Electronic Health Record (EHR-EDUS) during the study period. * Confirmed diagnosis of psoriasis documented in the Electronic Health Record (EHR-EDUS) of Hospital Calderón Guardia.
Exclusion criteria
* Clinical records insufficient to evaluate psoriasis severity, comorbidities, or therapeutic profile. * Patients managed exclusively with topical therapies. * Duplicate or inconsistent records, preventing accurate patient classification. * Cutaneous conditions not compatible with psoriasis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of Metabolic Comorbidities in Patients With Psoriasis | 2024-2025 | Proportion (%) of patients with documented diagnosis of obesity (BMI ≥30 kg/m²), diabetes mellitus (prior diagnosis or HbA1c ≥6.5%), hypertension (prior diagnosis or BP ≥140/90 mmHg), dyslipidemia (prior diagnosis or abnormal lipid profile), and metabolic syndrome. |
| Prevalence of Atherosclerotic Cardiovascular Disease | 2024-2025 | Proportion (%) of patients with documented history of coronary artery disease, myocardial infarction, angina/revascularization, ischemic stroke, or peripheral arterial disease. |
| Prevalence of Psoriatic Arthritis | 2024-2025 | Proportion (%) of patients with rheumatologist-confirmed diagnosis of psoriatic arthritis, including characterization of predominant clinical domain (peripheral arthritis, axial involvement, enthesitis, dactylitis). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Psoriasis Severity | 2024-2025 | Psoriasis Area and Severity Index (PASI), continuous score (0-72), categorized as mild (\<10), moderate (10-20), or severe (\>20). |
| Association Between Psoriasis Severity and Comorbidities | 2024-2025 | Statistical association between severity categories and presence of metabolic comorbidities, atherosclerotic disease, and psoriatic arthritis using chi-square, Fisher's exact test, t-test or Mann-Whitney U test. |
| Inflammatory and Metabolic Biomarkers | 2024-2025 | Continuous values of C-reactive protein, erythrocyte sedimentation rate, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, cardiac troponin, B-type natriuretic peptide, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, fasting plasma glucose, glycated hemoglobin, serum creatinine, estimated glomerular filtration rate, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and total bilirubin. |
Countries
Costa Rica
Contacts
CONTACTDaniel E Barquero-Orias, Dermatologist
Outcome results
None listed